MCS - Lifespan Edge - Page 3 of 3

Author: MCS

Brain Health Research

Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer’s disease from the AMBAR study

/ by MCS | Leave a Comment

The AMBAR trial studied the effects of plasma exchange (PE) on clinical laboratory parameters in Alzheimer’s disease (AD) patients. In this trial, 322 AD patients received six weeks of intensive therapeutic PE (TPE), followed by 12 months of monthly low-volume PE (LVPE). Patients were divided into groups receiving sham PE (placebo), low-dose albumin, low-dose albumin […]

Read more

Brain Health Research

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study

/ by MCS | Leave a Comment

This phase 2b/3 trial investigated the effects of plasma exchange (PE) with albumin replacement in patients with mild-to-moderate Alzheimer’s disease (AD). In the study, 347 patients were randomized into three PE treatment groups with varying doses of albumin and intravenous immunoglobulin, or a placebo group. Treatment involved six weeks of weekly conventional PE, followed by […]

Read more

Brain Health Research

Plasma exchange for Alzheimer’s disease Management by Albumin Replacement (AMBAR) trial: Study design and progress

/ by MCS | Leave a Comment

The AMBAR (Alzheimer Management By Albumin Replacement) study is a multicenter, randomized, placebo-controlled phase IIb/III trial investigating the effects of plasma exchange (PE) with therapeutic albumin replacement in patients with mild to moderate Alzheimer’s disease (AD). Previous studies indicated that PE with albumin may help remove amyloid-beta from plasma and cerebrospinal fluid, leading to improved […]

Read more

Brain Health Research

Results of Grifols’ AMBAR clinical trial published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association

/ by MCS | Leave a Comment

The results of Grifols’ AMBAR (Alzheimer Management by Albumin Replacement) clinical trial, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, show that plasma exchange with albumin replacement can slow Alzheimer’s disease progression. The therapy, which removes amyloid-beta protein bound to albumin from the blood, demonstrated benefits in cognitive and functional decline for […]

Read more

Brain Health Research

Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer’s disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study

/ by MCS | Leave a Comment

The 2021 AMBAR (Alzheimer’s Management by Albumin Replacement) study investigated the effects of plasma exchange (PE) with albumin replacement on neuropsychological, neuropsychiatric, and quality-of-life outcomes in patients with mild-to-moderate Alzheimer’s disease (AD). The study involved 347 patients divided into a placebo group and three PE treatment groups with varying doses of albumin and intravenous immunoglobulin […]

Read more

Brain Health Research

Proof of Concept in the AMBAR Study

/ by MCS | Leave a Comment

The article presents a proof of concept for an endpoint staging framework applied to the Alzheimer Management by Albumin Replacement (AMBAR) study. This framework aligns clinical trial endpoints (such as cognitive, functional, and quality-of-life measures) to specific Alzheimer’s disease (AD) stages where these outcomes are most relevant. The goal is to improve the sensitivity of […]

Read more

General Research

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis, Volume 38, Issue 2 p. 77-278

/ by MCS | Leave a Comment

The Ninth Edition of the Journal of Clinical Apheresis (JCA) Special Issue, published by the American Society for Apheresis (ASFA), provides updated guidelines on the use of therapeutic apheresis (TA) in treating human diseases. The edition incorporates a systematic review and evidence-based grading to assess and categorize TA’s use across various medical conditions. Maintaining the […]

Read more

Brain Health Research

Plasma exchange: An effective method to eliminate neurotoxic lipophilic chemicals from blood

/ by MCS | Leave a Comment

The article discusses plasma exchange (PE) as an effective method for removing neurotoxic lipophilic chemicals, particularly persistent organic pollutants (POPs), from the blood. POPs, which accumulate in human adipose tissue, are neurotoxic and have been linked to dementia risk. These pollutants are continuously released into circulation through lipolysis, posing a risk for individuals with obesity […]

Read more

Brain Health General

A brief history of Blood Component Exchange

/ by MCS | Leave a Comment

The Young Blood Institute discusses the potential benefits of therapeutic plasma exchange (TPE) for aging-related conditions, including Alzheimer’s disease. Traditionally used for autoimmune disorders, TPE removes and replaces plasma with components like albumin or immunoglobulins, helping clear harmful substances from the blood. TPE has shown promise in slowing progression in conditions like Alzheimer’s by potentially […]

Read more

To top